OTTAWA, ON – The Stem Cell Network (SCN) and Capital BioVentures (CBV) are pleased to announce a new partnership to accelerate the development and commercialization of regenerative medicine innovations in Canada…. Read More
Public funding for Pluvicto™ now available to patients with progressive PSMA-positive metastatic castration-resistant prostate cancer Reimbursement milestone underscores growing recognition of radioligand therapy’s impact in advanced prostate cancer MONTREAL, QC –… Read More
RESEARCH TRIANGLE PARK, NC – IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that… Read More
SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.1 MONTREAL, QC – AbbVie (NYSE: ABBV) announced that SKYRIZI®… Read More
GERMANTOWN, MD – uBriGene Biosciences(uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for its innovative iPSC Reprogramming mRNA-LNP Kit…. Read More
